Daxocox

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

enflicoxib

Available from:

Ecuphar NV

ATC code:

QM01AH95

INN (International Name):

enflicoxib

Therapeutic group:

Кучета

Therapeutic area:

Противовъзпалителни и антиревматични продукти

Therapeutic indications:

For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

Authorization status:

упълномощен

Authorization date:

2021-04-20

Patient Information leaflet

                                16
B. ЛИСТОВКА
17
ЛИСТОВКА:
DAXOCOX 15 MG ТАБЛЕТКИ ЗА КУЧЕТА
DAXOCOX 30 MG ТАБЛЕТКИ ЗА КУЧЕТА
DAXOCOX 45 MG ТАБЛЕТКИ ЗА КУЧЕТА
DAXOCOX 70 MG ТАБЛЕТКИ ЗА КУЧЕТА
DAXOCOX 100 MG ТАБЛЕТКИ ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба :
Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp, Белгия
Производител, отговорен за
освобождаване на партидата:
Lelypharma B.V.
Zuiveringweg 42
8243 PZ
Lelystad
Нидерландия
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Daxocox 15 mg таблетки за кучета
Daxocox 30 mg таблетки за кучета
Daxocox 45 mg таблетки за кучета
Daxocox 70 mg таблетки за кучета
Daxocox 100 mg таблетки за кучета
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦИЯ И
ЕКСЦИПИЕНТИТЕ
Всяка таблетка съдържа:
АКТИВНА СУБСТАНЦИЯ:
Enflicoxib
15 mg
Enflicoxib
30 mg
Enflicoxib
45 mg
Enflicoxib
70 mg
Enflicoxib
100 mg
ЕКСЦИПИЕНТИ:
Iron oxide black (E172) 0,26%
Iron oxide yellow (E172) 0,45%
Iron oxide red (E172) 0,50%
Кафяви, кръгли, изпъкнали таблетки.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
За
намаляване
на
болката
и
възпалението
при
остеоартрит
(или
дегенеративни
ставни
заболявания) при кучета.
18
5.
ПРОТИВОПОКАЗАНИЯ
Да не се използва при животни,
страдащи от стомашно-чревни
заболявания, ентеропатии,
свързани със загуба на протеини и
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Daxocox 15 mg таблетки за кучета
Daxocox 30 mg таблетки за кучета
Daxocox 45 mg таблетки за кучета
Daxocox 70 mg таблетки за кучета
Daxocox 100 mg таблетки за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка таблетка съдържа:
АКТИВНА СУБСТАНЦИЯ:
Enflicoxib
15 mg
Enflicoxib
30 mg
Enflicoxib
45 mg
Enflicoxib
70 mg
Enflicoxib
100 mg
ЕКСЦИПИЕНТИ:
Iron oxide black (E172) 0,26%
Iron oxide yellow (E172) 0,45%
Iron oxide red (E172) 0,50%
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Таблетки
Кафяви, кръгли, изпъкнали таблетки.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
За
намаляване
на
болката
и
възпалението
при
остеоартрит
(или
дегенеративни
ставни
заболявания) при кучета.
4.3
ПРОТИВОПОКАЗАНИЯ
Да не се използва при животни,
страдащи от стомашно-чревни
заболявания, ентеропатии,
свързани със загуба на протеини или
кръв, или хеморагични нарушения.
Да не се използва в случаи на нарушени
функции на бъбреците или черния дроб.
Да не се използва в случаи на сърдечна
недостатъчност.
Да не се използва при бременни или
л
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 16-07-2021
Public Assessment Report Public Assessment Report Spanish 16-07-2021
Patient Information leaflet Patient Information leaflet Czech 16-07-2021
Public Assessment Report Public Assessment Report Czech 16-07-2021
Patient Information leaflet Patient Information leaflet Danish 16-07-2021
Public Assessment Report Public Assessment Report Danish 16-07-2021
Patient Information leaflet Patient Information leaflet German 16-07-2021
Public Assessment Report Public Assessment Report German 16-07-2021
Patient Information leaflet Patient Information leaflet Estonian 16-07-2021
Public Assessment Report Public Assessment Report Estonian 16-07-2021
Patient Information leaflet Patient Information leaflet Greek 16-07-2021
Public Assessment Report Public Assessment Report Greek 16-07-2021
Patient Information leaflet Patient Information leaflet English 16-07-2021
Public Assessment Report Public Assessment Report English 16-07-2021
Patient Information leaflet Patient Information leaflet French 16-07-2021
Public Assessment Report Public Assessment Report French 16-07-2021
Patient Information leaflet Patient Information leaflet Italian 16-07-2021
Public Assessment Report Public Assessment Report Italian 16-07-2021
Patient Information leaflet Patient Information leaflet Latvian 16-07-2021
Public Assessment Report Public Assessment Report Latvian 16-07-2021
Patient Information leaflet Patient Information leaflet Lithuanian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-07-2021
Public Assessment Report Public Assessment Report Lithuanian 16-07-2021
Patient Information leaflet Patient Information leaflet Hungarian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 16-07-2021
Public Assessment Report Public Assessment Report Hungarian 16-07-2021
Patient Information leaflet Patient Information leaflet Maltese 16-07-2021
Public Assessment Report Public Assessment Report Maltese 16-07-2021
Patient Information leaflet Patient Information leaflet Dutch 16-07-2021
Public Assessment Report Public Assessment Report Dutch 16-07-2021
Patient Information leaflet Patient Information leaflet Polish 16-07-2021
Public Assessment Report Public Assessment Report Polish 16-07-2021
Patient Information leaflet Patient Information leaflet Portuguese 16-07-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 16-07-2021
Public Assessment Report Public Assessment Report Portuguese 16-07-2021
Patient Information leaflet Patient Information leaflet Romanian 16-07-2021
Public Assessment Report Public Assessment Report Romanian 16-07-2021
Patient Information leaflet Patient Information leaflet Slovak 16-07-2021
Public Assessment Report Public Assessment Report Slovak 16-07-2021
Patient Information leaflet Patient Information leaflet Slovenian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 16-07-2021
Public Assessment Report Public Assessment Report Slovenian 16-07-2021
Patient Information leaflet Patient Information leaflet Finnish 16-07-2021
Public Assessment Report Public Assessment Report Finnish 16-07-2021
Patient Information leaflet Patient Information leaflet Swedish 16-07-2021
Public Assessment Report Public Assessment Report Swedish 16-07-2021
Patient Information leaflet Patient Information leaflet Norwegian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 16-07-2021
Patient Information leaflet Patient Information leaflet Icelandic 16-07-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 16-07-2021
Patient Information leaflet Patient Information leaflet Croatian 16-07-2021
Public Assessment Report Public Assessment Report Croatian 16-07-2021

Search alerts related to this product

View documents history